Baxdrostat as a catalyst for precision hypertension: integrating pharmacogenomics, omics biomarkers, and digital phenotyping in resistant hypertension management
Clinical Hypertension · 2026 · 32 (1)
DOI: 10.5646/ch.2026.32.e27 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Hypertension, 2026. Verfasst von Asra Amjad und 2 weiteren Autor:innen. Beteiligte Einrichtung: Islamic International Medical College, Riphah International University, Rawalpindi, Pakistan. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Islamic International Medical College, Riphah International University, Rawalpindi, Pakistan.
- Azad Jammu and Kashmir Medical College, Muzaffarabad, Pakistan.
- Department of Pharmacy, University of Swabi, Swabi, Pakistan.
ORCID-Profile: Asra Amjad, Syeda Tayyaba Batool, Umair Ali
Zitieren
APA
Amjad, A., Batool, S. T., & Ali, U. (2026). Baxdrostat as a catalyst for precision hypertension: integrating pharmacogenomics, omics biomarkers, and digital phenotyping in resistant hypertension management. Clinical Hypertension, 32(1). https://doi.org/10.5646/ch.2026.32.e27
Vancouver
Amjad A, Batool ST, Ali U. Baxdrostat as a catalyst for precision hypertension: integrating pharmacogenomics, omics biomarkers, and digital phenotyping in resistant hypertension management. Clinical Hypertension. 2026;32(1). doi:10.5646/ch.2026.32.e27
BibTeX
@article{Amjad2026,
author = {Amjad, Asra and Batool, Syeda Tayyaba and Ali, Umair},
title = {Baxdrostat as a catalyst for precision hypertension: integrating pharmacogenomics, omics biomarkers, and digital phenotyping in resistant hypertension management},
journal = {Clinical Hypertension},
year = {2026},
volume = {32},
number = {1},
doi = {10.5646/ch.2026.32.e27}
}
EUVIMED